204 related articles for article (PubMed ID: 30129371)
21. Dual AAV Vectors for Stargardt Disease.
Trapani I
Methods Mol Biol; 2018; 1715():153-175. PubMed ID: 29188512
[TBL] [Abstract][Full Text] [Related]
22. Cell-autonomous lipid-handling defects in Stargardt iPSC-derived retinal pigment epithelium cells.
Farnoodian M; Bose D; Khristov V; Susaimanickam PJ; Maddileti S; Mariappan I; Abu-Asab M; Campos M; Villasmil R; Wan Q; Maminishkis A; McGaughey D; Barone F; Gundry RL; Riordon DR; Boheler KR; Sharma R; Bharti K
Stem Cell Reports; 2022 Nov; 17(11):2438-2450. PubMed ID: 36306781
[TBL] [Abstract][Full Text] [Related]
23. Stargardt disease and progress in therapeutic strategies.
Huang D; Heath Jeffery RC; Aung-Htut MT; McLenachan S; Fletcher S; Wilton SD; Chen FK
Ophthalmic Genet; 2022 Feb; 43(1):1-26. PubMed ID: 34455905
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel pathogenic
Xiang Q; Cao Y; Xu H; Guo Y; Yang Z; Xu L; Yuan L; Deng H
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30563929
[TBL] [Abstract][Full Text] [Related]
25. ATP-binding cassette subfamily A, member 4 intronic variants c.4773+3A>G and c.5461-10T>C cause Stargardt disease due to defective splicing.
Jonsson F; Westin IM; Österman L; Sandgren O; Burstedt M; Holmberg M; Golovleva I
Acta Ophthalmol; 2018 Nov; 96(7):737-743. PubMed ID: 29461686
[TBL] [Abstract][Full Text] [Related]
26. Fundus autofluorescence, spectral-domain optical coherence tomography, and histology correlations in a Stargardt disease mouse model.
Fang Y; Tschulakow A; Taubitz T; Illing B; Biesemeier A; Julien-Schraermeyer S; Radu RA; Jiang Z; Schraermeyer U
FASEB J; 2020 Mar; 34(3):3693-3714. PubMed ID: 31989709
[TBL] [Abstract][Full Text] [Related]
27. Study of Late-Onset Stargardt Type 1 Disease: Characteristics, Genetics, and Progression.
Li CHZ; Pas JAAH; Corradi Z; Hitti-Malin RJ; Hoogstede A; Runhart EH; Dhooge PPA; Collin RWJ; Cremers FPM; Hoyng CB
Ophthalmology; 2024 Jan; 131(1):87-97. PubMed ID: 37598860
[TBL] [Abstract][Full Text] [Related]
28. Localization and functional characterization of the p.Asn965Ser (N965S) ABCA4 variant in mice reveal pathogenic mechanisms underlying Stargardt macular degeneration.
Molday LL; Wahl D; Sarunic MV; Molday RS
Hum Mol Genet; 2018 Jan; 27(2):295-306. PubMed ID: 29145636
[TBL] [Abstract][Full Text] [Related]
29. Bisretinoid-mediated complement activation on retinal pigment epithelial cells is dependent on complement factor H haplotype.
Radu RA; Hu J; Jiang Z; Bok D
J Biol Chem; 2014 Mar; 289(13):9113-20. PubMed ID: 24550392
[TBL] [Abstract][Full Text] [Related]
30. Stargardt-Fundus flavimaculatus: recent advancements and treatment.
Haji Abdollahi S; Hirose T
Semin Ophthalmol; 2013; 28(5-6):372-6. PubMed ID: 24138045
[TBL] [Abstract][Full Text] [Related]
31. A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle.
Racz B; Varadi A; Kong J; Allikmets R; Pearson PG; Johnson G; Cioffi CL; Petrukhin K
J Biol Chem; 2018 Jul; 293(29):11574-11588. PubMed ID: 29871924
[TBL] [Abstract][Full Text] [Related]
32. Stem Cell-Based Therapy for Diseases of the Retinal Pigment Epithelium: From Bench to Bedside.
Sachdeva MM; Eliott D
Semin Ophthalmol; 2016; 31(1-2):25-9. PubMed ID: 26959126
[TBL] [Abstract][Full Text] [Related]
33. Advancing a Stem Cell Therapy for Age-Related Macular Degeneration.
O'Neill HC; Limnios IJ; Barnett NL
Curr Stem Cell Res Ther; 2020; 15(2):89-97. PubMed ID: 31854278
[TBL] [Abstract][Full Text] [Related]
34. Stargardt macular dystrophy and therapeutic approaches.
Fujinami K; Waheed N; Laich Y; Yang P; Fujinami-Yokokawa Y; Higgins JJ; Lu JT; Curtiss D; Clary C; Michaelides M
Br J Ophthalmol; 2024 Mar; 108(4):495-505. PubMed ID: 37940365
[TBL] [Abstract][Full Text] [Related]
35. Updates on Emerging Interventions for Autosomal Recessive
Wang L; Shah SM; Mangwani-Mordani S; Gregori NZ
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834872
[TBL] [Abstract][Full Text] [Related]
36. ABCA4-Associated Stargardt Disease.
Khan M; Cremers FPM
Klin Monbl Augenheilkd; 2020 Mar; 237(3):267-274. PubMed ID: 32016942
[TBL] [Abstract][Full Text] [Related]
37. Accelerated accumulation of lipofuscin pigments in the RPE of a mouse model for ABCA4-mediated retinal dystrophies following Vitamin A supplementation.
Radu RA; Yuan Q; Hu J; Peng JH; Lloyd M; Nusinowitz S; Bok D; Travis GH
Invest Ophthalmol Vis Sci; 2008 Sep; 49(9):3821-9. PubMed ID: 18515570
[TBL] [Abstract][Full Text] [Related]
38. Correlating the Expression and Functional Activity of ABCA4 Disease Variants With the Phenotype of Patients With Stargardt Disease.
Garces F; Jiang K; Molday LL; Stöhr H; Weber BH; Lyons CJ; Maberley D; Molday RS
Invest Ophthalmol Vis Sci; 2018 May; 59(6):2305-2315. PubMed ID: 29847635
[TBL] [Abstract][Full Text] [Related]
39. Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review.
Waugh N; Loveman E; Colquitt J; Royle P; Yeong JL; Hoad G; Lois N
Health Technol Assess; 2018 May; 22(27):1-168. PubMed ID: 29846169
[TBL] [Abstract][Full Text] [Related]
40. Aberrant early endosome biogenesis mediates complement activation in the retinal pigment epithelium in models of macular degeneration.
Kaur G; Tan LX; Rathnasamy G; La Cunza N; Germer CJ; Toops KA; Fernandes M; Blenkinsop TA; Lakkaraju A
Proc Natl Acad Sci U S A; 2018 Sep; 115(36):9014-9019. PubMed ID: 30126999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
